经颅磁刺激在难治性老年躯体化障碍治疗中的价值分析

The value of transcranial magnetic stimulation in the treatment of elderly patients with refractory somatization disorder

目的探讨经颅磁刺激在难治性老年躯体化障碍患者临床治疗中的价值。方法选取84例难治性老年躯体化障碍患者为研究对象,随机数字表法分为研究组和对照组各42例。对照组予以药物治疗方案;研究组在上述基础上联合重复经颅刺激治疗。观察对比两组受试者治疗前、治疗3周、6周时匹兹堡睡眠质量指数(PSQI)、汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)及症状自评量表(SCL-90)评估结果差异,记录其不良反应发生情况。结果治疗3周、6周后,两组受试者PSQI评分、HAMD、HAMA评分及SCL-90评分结果均较治疗前显著降低(P<0.05),且研究组低于对照组(P<0.05)。两组受试者不良反应发生率比较,差异无统计学意义(7.5%vs 7.3%,P>0.05)。结论经颅磁刺激疗法在促进难治性老年躯体化障碍患者病情转归、改善其预后质量等方面具有积极意义。

Objective To investigate the value of transcranial magnetic stimulationin the treatment of elderly patients with refractory somatization disorder. Methods Eighty-four elderly patients with refractory somatization disorder were randomized into study group and control group by the random number table method, with 42 cases in each group; The control group was treated with drugs; On the basis, the study group was treated with repeated transcranial stimulation. The sleep quality scores [ Pittsburgh sleep quality index （ PSQI ） 1, unhealthy emotion scores [ Hamilton Depression Scale （ HAMD ）, Hamilton Anxiety Scale （ HAMA ） ] and symptom checklist scores （ SCL-90 ） were ob- served and compared between the two groups before treatment, after 3 weeks and 6 weeks of treatment. The incidence of adverse reactions was recorded. Results After 3 weeks and 6 weeks of treatment, PSQI scores, HAMD scores, HAMA scores and SCL-90 scores of the two groups were significantly lower than those before treatment （ P〈0.05 ）, and the above scores in the study group were lower than those in the control group （P〈0.05） . There was no significant difference in the incidence of adverse reactions between the two groups （ 7.5 % vs 7.3 %, P〉0.05 ） . Conclusion Transcranial magnetic stimulation is of positive significance in promoting outcomes and improving prognosis of elderly patients with refractory somatization disorder.